Recent Posts
Connect with:
Tuesday / May 21.
HomeminewsTopical Squalamine for AMD

Topical Squalamine for AMD

Final results of the phase 2 IMPACT study of topical squalamine lactate in the treatment of neovascular agerelated macular degeneration have shown a trend toward increased efficacy in specific lesion types.

The IMPACT study evaluated the effects of OHR-102 (0.2 per cent squalamine lactate ophthalmic solution, Ohr Pharmaceutical) in combination with anti-VEGF in treatment-naïve patients with wet age-related macular degeneration and vision between 20/40 and 20/320.

Squalamine is a small molecule that counteracts multiple growth factors implicated in the angiogenic process, including VEGF and PDGF, Dr. Jeffrey Heier told delegates at the recent American Society of Retina Specialists meeting in Vienna. Patients received a Lucentis injection at day zero then were randomised 1-to-1 to squalamine topical therapy or placebo eye drops administered twice daily. They were followed monthly and re-treated with ranibizumab as needed based on strict OCTguided criteria. The number of retreatments were similar between the two groups.

“Outcomes were similar with respect to mean change in vision and three-line gainers, although there was a trend toward better outcomes in the squalamine group,” said Dr.Heier, adding that, in both the classic containing lesions and the smaller occult lesions less than four disc areas, there was a benefi t in mean change in vision and three-line gainers in the squalamine-treated group.

A phase 3 development program is under design. Dr. Heier consults to several pharmaceutical companies including Genentech, manufacturer of Lucentis.